Professional Services News / Visiongain Limited

Global Vaccine Contract Manufacturing Market Set to Grow to $2.9bn by 2023, According to Visiongain

Via: ReleaseWire

Updated 3:30 AM CDT, Mon, May 13,2019

London, England -- (SBWIRE) -- 05/13/2019 -- Visiongain has launched a new pharma report Global Vaccine Contract Manufacturing Market Report 2019-2029: Paediatric Vaccines, Adult Vaccines, Influenza Vaccines, Therapeutic Vaccines, Downstream Processing, Fill & Finish Operations, Analytical & QC Studies, Packaging, Upstream Processing, Mammalian Expression Systems, Bacterial Expression Systems, Yeast Expression Systems, Baculovirus/Insect Expression Systems and other Upstream Processing.

The vaccine manufacturing sector has traditionally been conservative in its approach, relying on traditional methods for vaccine production. There have been vaccine shortages within recent years, that were caused by national pandemics (such as avian flu) highlighted the shortcomings of some of these production methods. The increasing demand for vaccines will make it vital for the vaccine manufacturing industry to develop more-efficient methods for producing vaccines.

Download free sample pages

The report lead analyst commented that "Major fluctuations in demand are seen in the case of influenza, as was seen during pandemics over the last decade. The shortage of the number of doses was attributed to the slow and low-yielding traditional egg-based manufacturing technology that has been used for several decades by vaccine manufacturers. This egg-based manufacturing method has been meeting the demand for seasonal influenza vaccines but has been inefficient for meeting the rise in the global demand during pandemics. Several small and large vaccine manufacturers are now exploring innovative technology platforms for improving the scale of production of the influenza vaccine. Most of the recent developments in manufacturing platforms have been for this vaccine type. Thus, the vaccine manufacturing techniques are evolving, and this will stimulate the growth of the vaccine contract manufacturing market during the forecast period."

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on 0207 549 9987

Leading companies featured in the report include AbbVie, Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, Evonik Degusa, IDT Biologika, Lonza, Meridian Life Science, Nipro Corporation and others.

For more pharma reports,visit our website

Related reports:

Global Drug Discovery Outsourcing Market Forecast to 2028

mRNA vaccines and therapeutics market forecast 2019-2029

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on 0207 549 9987

About Visiongain
Visiongain is one of the fastest growing and most innovative independent business intelligence providers in Europe. Based in London, UK, Visiongain publishes independent and insightful market reports across a wide range of industry verticals, including automotive, chemical, cyber, defence, energy, pharmaceutical, materials and many others. Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. The company has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality and original business intelligence to depend upon.

For more information on this press release visit:
http://www.sbwire.com/press-releases/global-vaccine-contract-manufacturing-market-set-to-grow-to-29bn-by-2023-according-to-visiongain-1215372.htm

Media Relations Contact
Sara Peerun
+44 207 549 9987
Email: Click to Email Sara Peerun
Web: https://www.visiongain.com/